[Form 4] VOLITIONRX LTD Insider Trading Activity
Salvatore Thomas Butera, listed as an officer (CEO - Volition Veterinary) and director of VolitionRx Ltd (VNRX), reported transactions dated 09/28/2025 on a Form 4. The filing shows 5,230 shares of common stock disposed of at $0.605 per share by means of share retention by the issuer to satisfy tax withholding on the settlement of 19,125 restricted stock units; the filing states no shares were sold by the reporting person or the company. The reporting person beneficially owns 332,285 shares following the transaction, and 99,350 shares are jointly owned with his spouse.
- Tax withholding handled via share retention by the issuer rather than an open-market sale, avoiding immediate selling pressure
- Reporting person retains significant beneficial ownership (332,285 shares) after the RSU settlement, indicating continued alignment with shareholders
- Reduction in outstanding shares for the reporting person due to tax-withholding cancellation of 5,230 shares
- Joint ownership of 99,350 shares with spouse reduces the number of solely individually controlled shares
Insights
TL;DR Officer satisfied RSU tax withholding through company retention; no open-market sale reported, so immediate market impact is minimal.
The Form 4 documents a non-market disposal of 5,230 shares retained by the issuer to cover tax withholding on 19,125 RSUs. Because the shares were cancelled by the company for tax purposes rather than sold in the market, there is no direct selling pressure from the reporting person. The reporting person still beneficially owns 332,285 shares, indicating continued equity exposure. This disclosure is routine for RSU settlements and is informational rather than a material change in control or ownership.
TL;DR Disclosure aligns with standard insider reporting for RSU tax withholding; no governance concerns evident from the transaction details.
The filing clarifies the mechanism used to satisfy tax obligations upon RSU settlement, specifying that shares were retained by VolitionRx rather than sold by the insider. The report identifies the reporting person as an officer and director and notes joint ownership for 99,350 shares with his spouse. There are no disclosed resignations, option grants, or unusual derivative transactions in this Form 4 that would raise corporate governance flags.